Assess the current manufacturing landscape in the context of the COVID-19 pandemic. What are the short and long term implications for advanced therapeutics development?
Join advanced therapies stakeholders to take stock of the first half of 2020 and the short and long term implications of the ongoing COVID-19 pandemic. Hear an update on FDA regulatory guidance for manufacturers, take part in a virtual Q&A, and gain insight on current consortia initiatives and priorities for cell and gene therapy manufacturing and commercial development.
Speakers
Peter Marks MD, PhD
Director, Center for Biologics Evaluation and Research (CBER)
Food and Drug Administration (FDA)
Steven Goodman
Head of Drug Product Manufacturing
Bluebird Bio
Mark Plavsic
Chief Technology Officer and Head of Nonclinical Development
LYSOGENE
Kelvin H. Lee
Institute Director
National Institute for Innovation in Manufacturing Biopharmaceuticals (NIIMBL)
Craig Malzahn
Vice President, Manufacturing and Supply Chain
REGENXBIO Inc.
Rick Silva PhD
Executive Director, Clinical, Translation and Industry Collaborations
We use cookies and similar technologies to recognize your visits and preferences, as well as to measure the effectiveness of campaigns and analyze traffic. To learn more about cookies, including how to disable them, view our Cookie Policy
Unsupported Browser Detected
The browser you are using is not supported that will prevent you from accessing certain features of the website. We want you to have the best possible experience. For this you'll need to use a supported browser and upgrade to the latest version.